Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy

REFERENCES

• Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Joyce G, McCaffery DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001344: 817–823.
   Google Scholar
• Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected indi-viduals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS. 1999;13:2157–2164.
   PubMed Web of Science ®Google Scholar
• Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: the ATHENA cohort. AIDS. 2002;16:737–745.
   PubMed Web of Science ®Google Scholar
• Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials. 2002;3:89–98.
   PubMedGoogle Scholar
• Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401.
   PubMed Web of Science ®Google Scholar
• Little SJ, Nolte S, Routy JP, et al. Antiretroviral-drug resis-tance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394.
   PubMed Web of Science ®Google Scholar
• Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302–1307.
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O'Hearn M, et al. Efficacy of enfuvirtide plus an optimized background of antiretrovirals in treatment experienced HIV-1 positive patients in North America and Brazil. N Engl J Med. 2003;348:2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Katlama C, Arasteh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In: Program and abstracts of the 2nd International AIDS Soci-ety Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris. Abstract LB2.
   Google Scholar
• Beck JR. Markov models of natural history. J Clin Epidemiol. 1988;41:619–621.
   PubMed Web of Science ®Google Scholar
• Beck JR, Pauker SG. The Markov process in medical prog-nosis. Med Decis Making. 1983;3:419–458.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 cell T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201–207.
   PubMed Web of Science ®Google Scholar
• Trottier B, Arasteh K, Henry K, et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sep-tember 14–17, 2003; Chicago, IL. Abstract H–835.
   Google Scholar
• Cook J, Dasbach E, CopIan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy us-ing HIV RNA levels: application to a clinical trial [abstract]. AIDS Res Hum Retrovirus. 1999;15:499–508.
   PubMed Web of Science ®Google Scholar
• L'Informatore Farmaceutico. Milano:OEMF
   Google Scholar
• Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 200113: 733–741.
   Google Scholar
• Regione Lombardia. Aggiornamento delle tariffe delle prescrizioni ospedaliere in regime di ricovero. VII:941. 2000.
   Google Scholar
• Notizario ISS, anno 2002: vol. 15 n. 10; suppl. 1: COA. 2004.
   Google Scholar
• Weinstein MC, Go!die SJ, Losina E, et al. Use of genotyping resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001134: 440–450.
   Google Scholar
• Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic in-fections. JAMA. 1998;279:130–136.
   PubMed Web of Science ®Google Scholar
• Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applica-tions of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997;6:531–554.
   PubMed Web of Science ®Google Scholar
• Green J, Kleinman L, et al. Subcutaneous Injection Scale: Psychometric evaluation of a treatment satisfaction instru-ment associated with a novel HIV medication. HIV Clin Trials. 2002 ;3 (5): 387–395 .
   PubMedGoogle Scholar
• Cohen CJ, Clumeck N, Molina J-M, et al. Health-related quality of life with enfuvirtide (ENF; T20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr. 2004;37(1):1140–1146.
   PubMed Web of Science ®Google Scholar
• Cohen C, He!linger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials. 2003;4:347–357.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fu-sion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327–335.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
   Google Scholar
• Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 1998;339:380–386.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
   PubMed Web of Science ®Google Scholar
• Page JB, Lai S, Fletcher MA, et al. Predictors of survival in human immunodeficiency virus type 1-seropositive intra-venous drug users. Clin Diagn Lab Immunol. 1996;3:51–60.
   PubMedGoogle Scholar
• Perneger TV, Abrahamowicz M, Bartlett G, Yerly S. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study. J Investig Med. 2000;48:207–212.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short du-ration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346–355.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infec-tion. Ann Intern Med. 1997;126:946–954.
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001344: 824–831.
   Google Scholar
• Messori A, Trippoli S, Vaiani M. The cost effectiveness of antiretroviral therapy for HIV disease. N Engl J Med. 2001;345:68.
   PubMed Web of Science ®Google Scholar
• The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–52.
   PubMed Web of Science ®Google Scholar
• Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunologic changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F79–86.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59–F62.
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340:1683–1684.
   PubMed Web of Science ®Google Scholar
• Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 1999;13:677–683.
   PubMed Web of Science ®Google Scholar
• Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus repli-cation after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104:R13–R18.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recom-mendations of the International AIDS Society-USA Panel. JAMA. 2003;288:222–235.
   Web of Science ®Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9–17.
   PubMed Web of Science ®Google Scholar